News and Announcements
Bioactive Laboratories FY16 Update – Welcomes New Investors, Kicks Off New Drug Development Project & Celebrates TGA Milestone
- Published July 11, 2016 3:03PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Bioactive Laboratories welcomes its new investors & continues to invite SMSF investors to its register.
The Drug Development Division is powering ahead with the New Molecule Discovery project at the Eskitis Institute. The significance of this project, in creating a compound library, will add to Bioactive’s IP register of patents for commercial licensing.
The Complementary Medicine Division, creating optimised extracts, submitted its TGA New Substance application in June. This important milestone firms up customer relationships and opens the door to an FDA submission in the new financial year.
Bioactive have discovered new plant sourced molecules creating first-in-class stomach friendly anti-inflammatory and anti-microbial agents. These collectively service the global market of 7 billion people. An investor exit is planned within 2 years.